secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2023-10-19T23:59:59+00:00
Accession:  0001193125-23-258997
Event type: debt
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma draws $350M from revolver to fund Evrysdi royalty purchase
-------------------------------------------------------------------------

- Subsidiary borrowed $350M under $1.5B five-year unsecured revolver on Oct 18, 2023.
- Proceeds to partially fund previously announced purchase of additional Evrysdi royalties from PTC Therapeutics.
- Revolving credit facility originally dated Sept 15, 2021; amended Oct 31, 2022 (exhibit 10.1).
- Borrowing is within existing $1.5B capacity; no other material terms changed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312523258997/0001193125-23-258997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312523258997/d864803d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-258997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer